Your browser doesn't support javascript.
loading
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
Wu, Liviawati S; Hu, Yue; Gane, Edward J; Slaets, Leen; De Creus, An; Ding, Yanhua; Niu, Junqi; Schwabe, Christian; Goeyvaerts, Nele; Xu, Zhongnan; Huo, Dandan; Tuefferd, Marianne; Verbrugge, Inge; Van Remoortere, Pieter; Schwertschlag, Ullrich; Vandenbossche, Joris.
Afiliação
  • Wu LS; Janssen Research & Development, Brisbane, CA, USA.
  • Hu Y; 117971The First Hospital of Jilin University, Department of Hepatology, Changchun, Jilin, China.
  • Gane EJ; New Zealand Liver Transplant Unit, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
  • Slaets L; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • De Creus A; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Ding Y; 117971The First Hospital of Jilin University, Department of Hepatology, Changchun, Jilin, China.
  • Niu J; 117971The First Hospital of Jilin University, Department of Hepatology, Changchun, Jilin, China.
  • Schwabe C; Auckland Clinical Studies, New Zealand Clinical Research, Auckland, New Zealand.
  • Goeyvaerts N; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Xu Z; Chia Tai-Tianqing Pharmaceutical Group Co., Ltd, Nanjing, Jiangsu, China.
  • Huo D; Chia Tai-Tianqing Pharmaceutical Group Co., Ltd, Nanjing, Jiangsu, China.
  • Tuefferd M; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Verbrugge I; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
  • Van Remoortere P; Janssen Research & Development, LLC, Titusville, NJ, USA.
  • Schwertschlag U; Janssen Research & Development, Brisbane, CA, USA.
  • Vandenbossche J; Janssen Research & Development, 50148Janssen Pharmaceutica NV, Beerse, Belgium.
Antivir Ther ; 28(1): 13596535231151626, 2023 02.
Article em En | MEDLINE | ID: mdl-36691849
ABSTRACT

BACKGROUND:

JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B.

METHODS:

PK and PD data were pooled from 2 studies involving 90 participants (n = 74 JNJ-4964, dose range 0.2-1.8 mg; n = 16 placebo) in a fasted state. Food effects on PK were studied in 24 participants (1.2 or 1.25 mg). A population PK model and PK/PD models were developed to characterize the effect of JNJ-4964 plasma levels on the time course of IFN-α, IFN-γ-inducible protein 10 (IP-10 or CXCL10), IFN-stimulated gene 15 (ISG15), neopterin and lymphocytes following single and weekly dosing in healthy adults. Covariate effects, circadian rhythms and negative feedback were incorporated in the models.

RESULTS:

A 3-compartment linear PK model with transit absorption adequately described JNJ-4964 PK. Bioavailability was 44.2% in fed state relative to fasted conditions. Indirect response models with maximum effect (Emax) stimulation on production rate constant (kin) described IFN-α, IP-10, ISG15 and neopterin, while a precursor-dependent indirect response model with inhibitory effect described the transient lymphocyte reduction. Emax, EC50 and γ (steepness) estimates varied according to PD markers, with EC50 displaying substantial between-subject variability. Female and Asian race exhibited lower EC50, suggesting higher responsiveness.

CONCLUSIONS:

PK/PD models well characterized the time course of immune system markers in healthy adults. Our results supported sex and race as covariates on JNJ-4964 responsiveness, as well as circadian rhythms and negative feedback as homeostatic mechanisms that are relevant in TLR7-induced type I IFN responses.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor 7 Toll-Like / Quimiocina CXCL10 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor 7 Toll-Like / Quimiocina CXCL10 Idioma: En Ano de publicação: 2023 Tipo de documento: Article